logo
  

OCBC Bank H1 Earnings Rise

Oversea-Chinese Banking Corp. Ltd. or OCBC Bank (OCBC.SI,O39.SI), on Wednesday posted a rise in profit for the first-half, driven by higher net interest income and lower allowances. In addition, the lender has raised its interim dividend by 12 percent.

For the six-month period, the Singapore-headquartered company posted a Group net profit of S$2.837 billion, compared with S$2.661 billion a year ago. Total income was at S$5.522 billion, higher than S$5.486 billion last year.

Operating profit before allowances fell to S$3.563 billion, from last year's S$3.621 billion.

The bank posted its allowances at S$116 million, compared with S$393 million recorded for the first half of 2021.

Net interest income moved up 10 percent to S$3.203 billion, from last year's S$2.902 billion. However, non-interest earnings fell 10 percent to S$2.319 billion.

For the second quarter, Group net income stood at S$1.481 billion, up 28 percent from S$1.160 billion in the previous year quarter.

Net interest income was at S$1.700 billion, versus S$1.461 billion, during the corresponding period of 2021. Non-interest earnings also moved up to S$1.179 billion, from S$1.111 billion last year.

The lender has raised its interim dividend by 12 percent to 28 cents from the 25 cents interim dividend declared a year ago.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT